FDA's Transparency Initiative Enters The "What Is The Right Thing To Do" Phase: An Interview With Principal Deputy Commissioner Sharfstein

In June, FDA launched an internal Transparency Task Force to evaluate how to make the agency's decision-making process more accessible to the public. The agency held two public meetings and solicited comments from the public; the docket closed Nov. 6. FDA Principal Deputy Commissioner Joshua Sharfstein, who chairs the task force, spoke to "The Pink Sheet" about its initial findings